Standards for Reducing Risks Associated with ePMA for SACT

It is with great pleasure to announce that the BOPA Standards for Reducing Risks Associated with ePMA for SACT have been updated and can be found in the publication section of the members only section of the website.
 
These BOPA Standards for Reducing Risks Associated with Electronic Prescribing and Medicines Administration Systems (ePMA) for Systemic Anti-Cancer Therapies (SACT) outlines steps that can be considered to be best practice in reducing the risks of errors arising from the introduction and use of e-prescribing systems for SACT within organisations.
 
If you have any queries please direct them to [email protected]
 

Latest News

By BOPA on behalf of ISOPP on 29th July 2025

ISOPP July 2025 Newsletter

Volume 27 | No.7 | July 2025 From Netty Cracknell, ISOPP President Dear BOPA members, This month has been incredibly busy, and while there are moments I feel completely exhausted,…

Read article
By BOPA on 23rd July 2025

Third Annual Cancer Associated Thrombosis Summit: North of England

The NEONC CAT conference returns this year on the 8th of November, in Hull. As the UK’s only dedicated cancer associated thrombosis (CAT) conference, it presents a unique opportunity for…

Read article
By BOPA on 22nd July 2025

BOPA Questionnaire – Monitoring and Treatments for Immune-Related Myocarditis

The BOPA Immunotherapy Specialist Interest Group invites all BOPA members to complete this survey. This builds on our previous work exploring the known disparity across the UK with regards to…

Read article
By BOPA on 22nd July 2025

BOPA Member on the current state and future trajectory of pharmacy in cancer services

As president of the International Society of Oncology Pharmacy Practitioners and co-chair of the UK SACT Board, BOPA Member Netty Cracknell is championing the role of oncology pharmacy in delivering…

Read article